1. Inhibition of cellular RNA methyltransferase abrogates influenza virus capping and replication.
- Author
-
Tsukamoto Y, Hiono T, Yamada S, Matsuno K, Faist A, Claff T, Hou J, Namasivayam V, Vom Hemdt A, Sugimoto S, Ng JY, Christensen MH, Tesfamariam YM, Wolter S, Juranek S, Zillinger T, Bauer S, Hirokawa T, Schmidt FI, Kochs G, Shimojima M, Huang YS, Pichlmair A, Kümmerer BM, Sakoda Y, Schlee M, Brunotte L, Müller CE, Igarashi M, and Kato H
- Subjects
- Animals, Humans, Mice, RNA, Messenger metabolism, RNA, Viral biosynthesis, Streptomyces chemistry, Computer Simulation, A549 Cells, RNA Caps metabolism, Virus Replication drug effects, Alphainfluenzavirus drug effects, Betainfluenzavirus drug effects, Biological Products chemistry, Biological Products pharmacology, Antiviral Agents chemistry, Antiviral Agents pharmacology, Tubercidin analogs & derivatives, Tubercidin pharmacology, Methyltransferases antagonists & inhibitors, Enzyme Inhibitors chemistry, Enzyme Inhibitors pharmacology
- Abstract
Orthomyxo- and bunyaviruses steal the 5' cap portion of host RNAs to prime their own transcription in a process called "cap snatching." We report that RNA modification of the cap portion by host 2'-O-ribose methyltransferase 1 (MTr1) is essential for the initiation of influenza A and B virus replication, but not for other cap-snatching viruses. We identified with in silico compound screening and functional analysis a derivative of a natural product from Streptomyces , called trifluoromethyl-tubercidin (TFMT), that inhibits MTr1 through interaction at its S -adenosyl-l-methionine binding pocket to restrict influenza virus replication. Mechanistically, TFMT impairs the association of host cap RNAs with the viral polymerase basic protein 2 subunit in human lung explants and in vivo in mice. TFMT acts synergistically with approved anti-influenza drugs.
- Published
- 2023
- Full Text
- View/download PDF